{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:55:28Z","timestamp":1788432928040,"version":"build-2803163510"},"reference-count":118,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2998,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:p>The frequency of invasive fungal infections has increased dramatically in recent decades because of an expanding population at risk. Until now, treatment options for invasive mycoses have been primarily amphotericin B and the azoles, fluconazole and itraconazole. Traditional agents are limited by an inadequate spectrum of activity, drug resistance, toxicities, and drug\u2010drug interactions. The recent approval of caspofungin and voriconazole clearly has expanded the number of existing antifungal drugs available. However, the enthusiasm that accompanies their availability is counterbalanced by limited clinical experience, high drug acquisition costs, and distinctive toxicities. The pharmacologic characteristics, extent of clinical experience (efficacy and toxicity), and drug acquisition costs among available systemic antifungal agents are compared, with emphasis on the new agents. Also, recommendations on the role of each agent are provided according to the most common indications for systemic antifungal therapy: invasive candidiasis, invasive aspergillosis, and febrile neutropenia.<\/jats:p>","DOI":"10.1592\/phco.23.14.1441.31938","type":"journal-article","created":{"date-parts":[[2004,5,10]],"date-time":"2004-05-10T08:48:55Z","timestamp":1084178935000},"page":"1441-1462","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Systemic Antifungal Therapy: New Options, New Challenges"],"prefix":"10.1002","volume":"23","author":[{"given":"Annie","family":"Wong\u2010Beringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Kriengkauykiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/322606"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/520192"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/321811"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/318483"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.608"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_2_1_8_2","first-page":"371","volume-title":"Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations, or azoles [abstr]","author":"Maertens J.","year":"2000"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401273300407"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.1.78"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.4065\/73.12.1205"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.2.382"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray G.","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.12.961.33607"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/313498"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/514704"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/319201"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.40"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.3018"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/JCM.36.1.198-202.1998","article-title":"In vitro activity of the new triazole, voriconazole (UK\u2010109,496) against opportunistic filamentous and dimorphic fungi and common yeast pathogens","volume":"36","author":"Espinel\u2010Ingroff A.","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.169"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.43.6.1463","article-title":"In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients","volume":"34","author":"Hoban DJ","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1734-1736.2000"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.336"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1032-1037.2002"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1581-1582.2002"},{"key":"e_1_2_1_27_2","first-page":"839","volume-title":"Ravuconazole: multiple ascending oral dose study in healthy subjects [abstr]","author":"Grasela DM","year":"2000"},{"key":"e_1_2_1_28_2","first-page":"838","volume-title":"Ravuconazole single ascending oral dose study in healthy subjects [abstr]","author":"Olsen SJ","year":"2000"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08162-X"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1704-1713.2002"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10262"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.8.603.31529"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg089"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038020-00002"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64794-3"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010173200"},{"key":"e_1_2_1_37_2","volume-title":"Voriconazole background document for the antiviral drug products advisory committee meeting","author":"Food and Drug Administration.","year":"2003"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1723-1727.2002"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/JCM.36.5.1436-1438.1998","article-title":"Use of voriconazole in treatment of Scedosporium apiospermum infection: case report","volume":"36","author":"Girmenia C.","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.8.928d"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.62-68.2002"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2000.020307.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/313817"},{"key":"e_1_2_1_44_2","first-page":"F77","volume-title":"UK\u2010109,496, a novel, wide\u2010spectrum triazole derivative for the treatment of fungal infections: disposition in animals [abstr]","author":"Jezequel SG","year":"1995"},{"key":"e_1_2_1_45_2","first-page":"663","article-title":"Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia","volume":"97","author":"Scwartz S.","year":"1997","journal-title":"Br J Haematol"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2546-2553.2002"},{"key":"e_1_2_1_47_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/00912700222011445","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study","volume":"42","author":"Lazarus HM","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_48_2","volume-title":"Vfend (voriconazole) package insert","author":"Pfizer.","year":"2002"},{"key":"e_1_2_1_49_2","unstructured":"Food and Drug Administration.Briefing document for voriconazole. FDA Antiviral Drugs Advisory Committee October 4 2001. Available fromhttp:www.fda.govohrmsdocketsac01briefing3792b2_01_Pfizer.pdf. AccessedFebruary 28 2003."},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01499.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.3091-3093.2002"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121911"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00909.x"},{"key":"e_1_2_1_54_2","first-page":"A\u201018","volume-title":"Investigation of the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials [abstr]","author":"Tan KKC","year":"2001"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1086\/343746"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1086\/324620"},{"key":"e_1_2_1_57_2","first-page":"A\u2010639","volume-title":"Visual effects with voriconazole [abstr]","author":"Tomaszewski K.","year":"2001"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1086\/375080"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2310-2318.2000"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00130-8"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2326"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050283"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.1985"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1086\/317614"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3394-3400.2002"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00050-9"},{"key":"e_1_2_1_68_2","first-page":"M\u2010230","volume-title":"Tolerance and fungicidality in vitro of caspofungin, micafungin, and anidulafungin against Candida guillermondii [abstr]","author":"Moore CB","year":"2002"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1773-1780.2002"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3634-3636.2002"},{"key":"e_1_2_1_71_2","first-page":"M\u20101813","volume-title":"Combinations of antifungal agents against Candida albicans biofilms in vitro [abstr]","author":"Bachmann SP","year":"2002"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1480"},{"key":"e_1_2_1_73_2","first-page":"M\u2010856","volume-title":"In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus [abstr]","author":"Oshaughnessy EM","year":"2002"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.245-247.2002"},{"key":"e_1_2_1_75_2","volume-title":"In vitro activity of amphotericin B lipid complex in 2\u2010drug combination with caspofungin against Aspergillus fumigatus [abstr]","author":"Chandrasekar PH","year":"2002"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.3039-3041.2002"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2564-2568.2002"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg090"},{"key":"e_1_2_1_79_2","volume-title":"Medical review","author":"Food and Drug Administration.","year":"2003"},{"key":"e_1_2_1_80_2","first-page":"A\u201013","volume-title":"Drug interactions between caspofungin and tacrolimus [abstr]","author":"Stone J.","year":"2001"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021585"},{"key":"e_1_2_1_82_2","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.1995.00430220087009","article-title":"Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study","volume":"155","author":"Nguyen MH","year":"1995","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.6.1531"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.10.3551-3557.2002"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.2.267"},{"key":"e_1_2_1_86_2","volume-title":"Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstr]","author":"Anaissie EJ","year":"1995"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411173312001"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2001.00649.x"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.964"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)80072-6"},{"key":"e_1_2_1_91_2","first-page":"191","article-title":"A meta\u2010analysis of fluconazole versus amphotericin B for treatment of invasive Candida infections","volume":"9","author":"Zerr DM","year":"2002","journal-title":"J Clin Outcomes Manage"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1086\/374850"},{"key":"e_1_2_1_94_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1128\/JCM.36.1.153-156.1998","article-title":"Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method","volume":"36","author":"Revankar SG","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_95_2","volume-title":"Voriconazole (Vfend) NDA 21\u2013266 and 21\u2013267","author":"Food and Drug Administration.","year":"2003"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1086\/374557"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1086\/513943"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200007000-00006"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_2_1_100_2","first-page":"M\u2010856","volume-title":"Update of multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients [abstr]","author":"Maertens J.","year":"2002"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x"},{"key":"e_1_2_1_102_2","first-page":"M\u2010859","volume-title":"Refractory invasive fungal infections in patients (pts) with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B [abstr]","author":"Thiebaut A.","year":"2002"},{"key":"e_1_2_1_103_2","first-page":"M\u2010860","volume-title":"Combination antifungals for treatment of pulmonary invasive aspergillosis (IA) refractory to amphotericin B (AmB) in leukaemia patients [abstr]","author":"Gentina T.","year":"2002"},{"key":"e_1_2_1_104_2","first-page":"M\u20101820","volume-title":"Efficacy and toxicity of the caspofungin\/liposomal amphotericin B (CAS\/LipoAMB) combination in documented or possible invasive aspergillosis (IA) in patients (pts) with hematologic malignancies [abstr]","author":"Kontoyiannis DP","year":"2002"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1086\/320871"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1086\/339215"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1086\/338636"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2476"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00457-X"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-6-200109180-00010"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1086\/514672"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1086\/317451"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00246-0"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200201243460403"},{"key":"e_1_2_1_117_2","unstructured":"Food and Drug Administration.FDA presentation on NDA 21\u2013266 Vfend (voriconazole) tablets and NDA 21\u2013267 Vfend I.V. (voriconazole) for infusion. Food and Drug Administration Antiviral Drugs Advisory Committee (AVAC) Meeting Oct 4 2001. Available fromhttp:www.fda.govohrmsdocketsac01slides3792s2.htm. AccessedFebruary 28 2003."},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.31"},{"key":"e_1_2_1_119_2","volume-title":"Sporanox (itraconazole) package insert","author":"Janssen Pharmaceutica Products, L.P.","year":"2002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.23.14.1441.31938","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.23.14.1441.31938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:22:30Z","timestamp":1761067350000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.23.14.1441.31938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":118,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1592\/phco.23.14.1441.31938"],"URL":"https:\/\/doi.org\/10.1592\/phco.23.14.1441.31938","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}